Development of a research agenda for evaluation of interventional therapies for chronic cerebrospinal venous insufficiency: Proceedings from a multidisciplinary research consensus panel

Gary P. Siskin, Ziv J. Haskal, Gordon McLennan, Michael D. Dake, E. Mark Haacke, Sandy McDonald, Walter Royal, Suresh Vedantham, David Hubbard, Salvatore J. Sclafani, R. Torrance Andrews, Heidi Sauder

Research output: Contribution to journalEditorial

11 Citations (Scopus)

Abstract

The committee came to the general consensus that the mechanisms for evaluating patients with MS for jugular and azygous venous compromise and the value of treating these lesions with angioplasty warrant careful, well designed additional study. The committee believed the specific parameters needed for a large-scale, pivotal multicenter trial were not necessarily available at this time, but that these types of trials are the mandatory goal for study of CCSVI. Prospective safety and efficacy trials should be conducted in well defined and potentially smaller controlled populations under institutional review board approval. In addition, it is critical to support and continue the basic science work under way to better understand the relationship between venous stenoses and hypertension and the subsequent contribution of CCSVI to patients with MS. Animal models will likely prove useful, though inflammatory mediators may be assessed with serum sampling in the context of human trials. There will be many practitioners who will offer endovascular therapy to patients with MS in advance of the availability of definitive peer-reviewed data in support of that practice. It was the general hope of the committee that this work would lead to additional peer-reviewed studies generating data that clarify the role in MS of treating venous disease with angioplasty and possibly stent placement and the potential adverse events associated with these interventions (65). If additional studies confirm the initial reports in favor of CCSVI diagnosis and treatment, and appropriate study cohorts and standardized procedural technique and reporting are developed, it will be appropriate to pursue prospective multicenter trials. Enrollment in these trials will require the following: (i) confirmation of the diagnosis of MS based on currently accepted criteria; (ii) assessment of disease activity with conventional MR imaging; (iii) determination of clinical and functional status; (iv) listing of previous treatment for MS or other significant medical issues; (v) noninvasive screening documentation of venous disease with US and/or MR imaging/venography; and (vi) catheter-based venographic documentation of venous stenoses. Randomization against catheter venography without angioplasty would be required, with blinding of research personnel and examining neurologists. The potential role of stents would emerge from discussions of trial design. Imaging follow-up and clinical assessments might occur at 3, 6, 9, and 12 months after treatment, with a crossover permissible after a period yet to be defined. This type of study defines an ultimate goal in determining the contributory role of CCSVI and catheter-based interventions in patients affected with MS.

Original languageEnglish (US)
Pages (from-to)587-593
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume22
Issue number5
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Venous Insufficiency
Consensus
Angioplasty
Catheters
Phlebography
Research
Documentation
Multicenter Studies
Stents
Hope
Pathologic Constriction
Research Ethics Committees
Therapeutics
Random Allocation
Cohort Studies
Neck
Animal Models
Research Personnel
Hypertension
Safety

Keywords

  • CCSVI
  • central nervous system
  • chronic cerebrospinal venous insufficiency
  • CNS
  • MS
  • multiple sclerosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Development of a research agenda for evaluation of interventional therapies for chronic cerebrospinal venous insufficiency : Proceedings from a multidisciplinary research consensus panel. / Siskin, Gary P.; Haskal, Ziv J.; McLennan, Gordon; Dake, Michael D.; Haacke, E. Mark; McDonald, Sandy; Royal, Walter; Vedantham, Suresh; Hubbard, David; Sclafani, Salvatore J.; Andrews, R. Torrance; Sauder, Heidi.

In: Journal of Vascular and Interventional Radiology, Vol. 22, No. 5, 05.2011, p. 587-593.

Research output: Contribution to journalEditorial

Siskin, Gary P. ; Haskal, Ziv J. ; McLennan, Gordon ; Dake, Michael D. ; Haacke, E. Mark ; McDonald, Sandy ; Royal, Walter ; Vedantham, Suresh ; Hubbard, David ; Sclafani, Salvatore J. ; Andrews, R. Torrance ; Sauder, Heidi. / Development of a research agenda for evaluation of interventional therapies for chronic cerebrospinal venous insufficiency : Proceedings from a multidisciplinary research consensus panel. In: Journal of Vascular and Interventional Radiology. 2011 ; Vol. 22, No. 5. pp. 587-593.
@article{e5572a25dbcc4d48a47344b91149541c,
title = "Development of a research agenda for evaluation of interventional therapies for chronic cerebrospinal venous insufficiency: Proceedings from a multidisciplinary research consensus panel",
abstract = "The committee came to the general consensus that the mechanisms for evaluating patients with MS for jugular and azygous venous compromise and the value of treating these lesions with angioplasty warrant careful, well designed additional study. The committee believed the specific parameters needed for a large-scale, pivotal multicenter trial were not necessarily available at this time, but that these types of trials are the mandatory goal for study of CCSVI. Prospective safety and efficacy trials should be conducted in well defined and potentially smaller controlled populations under institutional review board approval. In addition, it is critical to support and continue the basic science work under way to better understand the relationship between venous stenoses and hypertension and the subsequent contribution of CCSVI to patients with MS. Animal models will likely prove useful, though inflammatory mediators may be assessed with serum sampling in the context of human trials. There will be many practitioners who will offer endovascular therapy to patients with MS in advance of the availability of definitive peer-reviewed data in support of that practice. It was the general hope of the committee that this work would lead to additional peer-reviewed studies generating data that clarify the role in MS of treating venous disease with angioplasty and possibly stent placement and the potential adverse events associated with these interventions (65). If additional studies confirm the initial reports in favor of CCSVI diagnosis and treatment, and appropriate study cohorts and standardized procedural technique and reporting are developed, it will be appropriate to pursue prospective multicenter trials. Enrollment in these trials will require the following: (i) confirmation of the diagnosis of MS based on currently accepted criteria; (ii) assessment of disease activity with conventional MR imaging; (iii) determination of clinical and functional status; (iv) listing of previous treatment for MS or other significant medical issues; (v) noninvasive screening documentation of venous disease with US and/or MR imaging/venography; and (vi) catheter-based venographic documentation of venous stenoses. Randomization against catheter venography without angioplasty would be required, with blinding of research personnel and examining neurologists. The potential role of stents would emerge from discussions of trial design. Imaging follow-up and clinical assessments might occur at 3, 6, 9, and 12 months after treatment, with a crossover permissible after a period yet to be defined. This type of study defines an ultimate goal in determining the contributory role of CCSVI and catheter-based interventions in patients affected with MS.",
keywords = "CCSVI, central nervous system, chronic cerebrospinal venous insufficiency, CNS, MS, multiple sclerosis",
author = "Siskin, {Gary P.} and Haskal, {Ziv J.} and Gordon McLennan and Dake, {Michael D.} and Haacke, {E. Mark} and Sandy McDonald and Walter Royal and Suresh Vedantham and David Hubbard and Sclafani, {Salvatore J.} and Andrews, {R. Torrance} and Heidi Sauder",
year = "2011",
month = "5",
doi = "10.1016/j.jvir.2011.03.007",
language = "English (US)",
volume = "22",
pages = "587--593",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Development of a research agenda for evaluation of interventional therapies for chronic cerebrospinal venous insufficiency

T2 - Proceedings from a multidisciplinary research consensus panel

AU - Siskin, Gary P.

AU - Haskal, Ziv J.

AU - McLennan, Gordon

AU - Dake, Michael D.

AU - Haacke, E. Mark

AU - McDonald, Sandy

AU - Royal, Walter

AU - Vedantham, Suresh

AU - Hubbard, David

AU - Sclafani, Salvatore J.

AU - Andrews, R. Torrance

AU - Sauder, Heidi

PY - 2011/5

Y1 - 2011/5

N2 - The committee came to the general consensus that the mechanisms for evaluating patients with MS for jugular and azygous venous compromise and the value of treating these lesions with angioplasty warrant careful, well designed additional study. The committee believed the specific parameters needed for a large-scale, pivotal multicenter trial were not necessarily available at this time, but that these types of trials are the mandatory goal for study of CCSVI. Prospective safety and efficacy trials should be conducted in well defined and potentially smaller controlled populations under institutional review board approval. In addition, it is critical to support and continue the basic science work under way to better understand the relationship between venous stenoses and hypertension and the subsequent contribution of CCSVI to patients with MS. Animal models will likely prove useful, though inflammatory mediators may be assessed with serum sampling in the context of human trials. There will be many practitioners who will offer endovascular therapy to patients with MS in advance of the availability of definitive peer-reviewed data in support of that practice. It was the general hope of the committee that this work would lead to additional peer-reviewed studies generating data that clarify the role in MS of treating venous disease with angioplasty and possibly stent placement and the potential adverse events associated with these interventions (65). If additional studies confirm the initial reports in favor of CCSVI diagnosis and treatment, and appropriate study cohorts and standardized procedural technique and reporting are developed, it will be appropriate to pursue prospective multicenter trials. Enrollment in these trials will require the following: (i) confirmation of the diagnosis of MS based on currently accepted criteria; (ii) assessment of disease activity with conventional MR imaging; (iii) determination of clinical and functional status; (iv) listing of previous treatment for MS or other significant medical issues; (v) noninvasive screening documentation of venous disease with US and/or MR imaging/venography; and (vi) catheter-based venographic documentation of venous stenoses. Randomization against catheter venography without angioplasty would be required, with blinding of research personnel and examining neurologists. The potential role of stents would emerge from discussions of trial design. Imaging follow-up and clinical assessments might occur at 3, 6, 9, and 12 months after treatment, with a crossover permissible after a period yet to be defined. This type of study defines an ultimate goal in determining the contributory role of CCSVI and catheter-based interventions in patients affected with MS.

AB - The committee came to the general consensus that the mechanisms for evaluating patients with MS for jugular and azygous venous compromise and the value of treating these lesions with angioplasty warrant careful, well designed additional study. The committee believed the specific parameters needed for a large-scale, pivotal multicenter trial were not necessarily available at this time, but that these types of trials are the mandatory goal for study of CCSVI. Prospective safety and efficacy trials should be conducted in well defined and potentially smaller controlled populations under institutional review board approval. In addition, it is critical to support and continue the basic science work under way to better understand the relationship between venous stenoses and hypertension and the subsequent contribution of CCSVI to patients with MS. Animal models will likely prove useful, though inflammatory mediators may be assessed with serum sampling in the context of human trials. There will be many practitioners who will offer endovascular therapy to patients with MS in advance of the availability of definitive peer-reviewed data in support of that practice. It was the general hope of the committee that this work would lead to additional peer-reviewed studies generating data that clarify the role in MS of treating venous disease with angioplasty and possibly stent placement and the potential adverse events associated with these interventions (65). If additional studies confirm the initial reports in favor of CCSVI diagnosis and treatment, and appropriate study cohorts and standardized procedural technique and reporting are developed, it will be appropriate to pursue prospective multicenter trials. Enrollment in these trials will require the following: (i) confirmation of the diagnosis of MS based on currently accepted criteria; (ii) assessment of disease activity with conventional MR imaging; (iii) determination of clinical and functional status; (iv) listing of previous treatment for MS or other significant medical issues; (v) noninvasive screening documentation of venous disease with US and/or MR imaging/venography; and (vi) catheter-based venographic documentation of venous stenoses. Randomization against catheter venography without angioplasty would be required, with blinding of research personnel and examining neurologists. The potential role of stents would emerge from discussions of trial design. Imaging follow-up and clinical assessments might occur at 3, 6, 9, and 12 months after treatment, with a crossover permissible after a period yet to be defined. This type of study defines an ultimate goal in determining the contributory role of CCSVI and catheter-based interventions in patients affected with MS.

KW - CCSVI

KW - central nervous system

KW - chronic cerebrospinal venous insufficiency

KW - CNS

KW - MS

KW - multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=79955387155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955387155&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2011.03.007

DO - 10.1016/j.jvir.2011.03.007

M3 - Editorial

C2 - 21514515

AN - SCOPUS:79955387155

VL - 22

SP - 587

EP - 593

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 5

ER -